A man with graying hair sits at a kitchen table at night, seen from behind with his chin resting on his hand. A lamp lights a laptop showing a page of lab results, a phone lying face-down, a cup of tea and a pill organizer, and the window beyond him shows the first gray of dawn.

Never Settled

The life of a transplant recipient is never quite settled. There’s always something weighing on your mind: the possibility of rejection, the chance the organ simply stops working, the infections and cancers that come with a suppressed immune system. Something. A month ago I wrote that expecting to die had been a settled condition, and that what replaced it has no edges. Two years out, I can report that it still doesn’t.


The Patient With One Patient

Then there are those of us who have learned to read the tests and know what they mean. We read the medical journals, the clinical reports, the studies. I’ve often said that my doctors have dozens, even hundreds, of patients, and I have exactly one. That kind of attention is a double-edged sword. It catches things early, and it catches things that turn out to be nothing, and from the inside the two look exactly alike for a while.

My two-year evaluation was on Monday, November 9, two years to the day after the transplant: a right and left heart catheterization with intravascular ultrasound, a biopsy, an echocardiogram and a full run of bloodwork. What that kind of day involves is laid out in The Follow-Up Gauntlet. Most of the results came back that afternoon and over the next couple of days. Two came back later.


The Two-Year Numbers

The biggest question going in was the vasculopathy. At my one-year evaluation, the team found cardiac allograft vasculopathy, a narrowing of the vessels that feed the transplanted heart itself. It’s a different process from the ordinary atherosclerosis most people know, and a year of medication changes followed. This year’s intravascular ultrasound showed no change in the thickness of the vessel wall from last year. The cath report calls it minimal and unchanged. The pressures inside the heart were normal, and so was the output. My ejection fraction came in at 52 percent, inside the range it has held across nine echocardiograms since early 2025.

The biopsy came back 1A/1R, mild cellular rejection, the kind that doesn’t call for treatment. The grading scale runs from 0R, no rejection, upward, and 1R happens; it’s common, and it’s been my result on eight of twelve biopsies since the transplant. Getting a 0R at my one-year evaluation was kind of cool, so this one is a small disappointment, but not a big deal. The staining that looks for antibody involvement, called C4d, was negative, as it has been every time.

The bloodwork was mostly good news. My kidney function is better now than it was in the last year before the transplant. The anti-donor antibody panel came back negative across the board, with no donor-specific antibodies detected, as on every draw since the transplant. My A1c was 6.1, down from 7.6 in January, and I weighed in at 220 pounds, down 23 from a year ago. The one number that gave me pause was my PSA, up to 5.4 from 3.0 a year ago, though still well below the 9.0 it reached before the transplant, in October 2024. It’s mildly disconcerting but not worth getting worked up over; I’ll follow up with a urologist and repeat the test in a few months.

So the first wave of results was good. Then I waited for the last two.


The Other Shoe

Prospera measures how much of the DNA floating free in the bloodstream comes from the donor heart. A heart under attack sheds more of it, so a low number is a good number; I explained it in more detail in The Blood is the Life. Mine came back below 0.08 percent, low risk, the same as every draw since the summer of 2025.

The MMDx was less clear. It’s a molecular reading of a piece of the biopsy: rather than a pathologist looking at tissue under a microscope, it measures which genes are active in the sample and uses machine learning to compare that pattern against a reference set of earlier heart biopsies. The manufacturer is explicit that it’s meant to supplement the pathologist’s read, not replace it. Mine flagged possible antibody-mediated rejection. It found no sign of the cellular kind. In the same report, it hedged: the result came from a single small piece of tissue, and sampling error was possible.

It was the first time I’d seen anything like that in a while, and I saw it on Saturday, November 14. That meant waiting until Monday to hear from the people who actually know how to weigh it.

This is the nagging doubt that sits in the back of every transplant recipient’s head, the other shoe every one of us is waiting to hear drop. Some of us were about to die before the transplant became a reality. I was one of them, running on an Impella pump with an ejection fraction in the single digits. It might seem odd that the possibility of dying would still jostle someone who came that close. It does.


Saturday to Monday

I know the MMDx has an imperfect record. I know every other test came back reasonably well, the biopsy included, even with its 1R. None of that changes what happens when you see those words on a report. The anxiety ratchets up. Could I have slipped into some kind of rejection? I’m still reasonably active, and I wasn’t having any symptoms that would give me pause. I went through all of it anyway, more than once.

These are the things that go through your mind as a transplant patient. Add last year’s vasculopathy finding, and it’s been a stressful year on the health front, with many a sleepless night. The weekend was no different.

I sent my coordinator three questions, and otherwise told no one about the result, knowing that sharing it with the people I love wasn’t the answer. That’s something else many of us do: keep possibly bad news close to the vest until it’s confirmed. It’s how I’m wired, and it maybe isn’t the standard. Plenty of recipients would have called someone within the hour, and there’s nothing wrong with that. Waiting alone isn’t braver. It’s just quieter.

On Monday morning, November 16, Parker from the transplant team called instead of sending a message. He said he wouldn’t be concerned at all. The C4d staining was negative, the Prospera was clean, the antibodies were negative, and he reads all of these tests “as a bulk, in a group.” Injury in a biopsy sample can sometimes push the MMDx toward a false positive for antibody-mediated rejection. If everything were pointing to it, he said, that would be one thing. With everything else pointing the other way, it was probably just an over-read. Then he told me to let them worry about it and enjoy every day.

So I started breathing again. Just a little.


Year Three

I heard myself tell him on that call that it’s hard to believe I’m actually probably going to live. I meant it. Just over two years ago, I was certain I’d reached the end of the runway. Now the vasculopathy appears to be holding, the heart appears healthy overall, and it looks like I’ll be sticking around a while longer.

Each year since the transplant has had its own job. Year one was recovery, pure and simple, and nothing more. Year two was the vasculopathy and blood sugars that ran wild, especially once sirolimus and tacrolimus started working against me together. That was bad, and it took a long time to bring under control. Between Jardiance, Rybelsus (the pill form of the drug in Ozempic) and some changes to how I eat, it has finally settled into something manageable.

Year three has a single-minded goal: lose the weight and rebuild a life that has been on hold for the better part of ten years. The board was cleared a while ago. It’s time to build on it.

I’m not settled. I’m a little less unsettled than I was on Saturday, and I suspect a fitful night’s rest is still in my immediate future.


Discover more from One More Beat

Subscribe to get the latest posts sent to your email.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *